Gadopiclenol Enables Safer Pediatric Brain MRI with Half the Gadolinium Dose: Study Suggests
USA: A recent study published in the American Journal of Roentgenology supports the use of gadopiclenol as a lower-dose alternative to conventional gadolinium-based contrast agents (GBCAs) in pediatric brain MRI. The research, led by Dr. Sergio Valencia of Massachusetts General Hospital and Harvard Medical School, highlights the potential of gadopiclenol to minimize cumulative gadolinium exposure in children who require repeated imaging.
Gadopiclenol, a macrocyclic contrast agent approved by the U.S. FDA in 2022, is known for its high T1 relaxivity, enabling significant dose reduction compared to other GBCAs. This study compared the performance of gadopiclenol at 0.05 mmol/kg with gadoterate meglumine at the standard 0.1 mmol/kg in the same pediatric patients to assess contrast enhancement quality.
The retrospective study included 38 children (mean age 11.1 years) who underwent both types of contrast-enhanced brain MRI within a six-month span, using identical imaging protocols and field strength. Researchers analyzed three key postcontrast MRI sequences: 3D T1-weighted fast-spin echo (FSE), 3D T1-weighted gradient-recalled echo (GRE), and 2D fluid-attenuated inversion-recovery (FLAIR).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.